Downregulation of lactosylceramide synthases B4GALT5 or B4GALT6 alters glycosphingolipid profiles and enhances oxaliplatin sensitivity in colon cancer cells
Randomized trial evaluates chemosensitivity enhancement in colon cancer cells through LacCer synthase inhibition, suggesting a novel therapeutic approach.
Key Points
This study investigates how inhibiting lactosylceramide synthesis affects colon cancer cell survival and sensitivity to oxaliplatin.
CRISPR/Cas9-mediated gene knockdown of B4GALT5 and B4GALT6 in DLD-1 colon adenocarcinoma cells.
Assessment of glycosphingolipid levels and cell viability after oxaliplatin treatment.
Measurement of apoptosis markers, including caspase activation and endoplasmic reticulum stress response.
LCS-knockdown cells showed reduced LacCer and complex GSL levels (e.g., GM3 and GM1a).
Cell viability decreased with oxaliplatin treatment, indicating enhanced sensitivity (exact rates not provided).
Increased levels of apoptosis markers, such as cleaved caspases, and decreased ATF6 levels were observed.